UY27039A1 - Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción - Google Patents
Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producciónInfo
- Publication number
- UY27039A1 UY27039A1 UY27039A UY27039A UY27039A1 UY 27039 A1 UY27039 A1 UY 27039A1 UY 27039 A UY27039 A UY 27039A UY 27039 A UY27039 A UY 27039A UY 27039 A1 UY27039 A1 UY 27039A1
- Authority
- UY
- Uruguay
- Prior art keywords
- forms
- ureido
- bromo
- ilbutil
- isotiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a las formas de sal hidrocloruro, hidrobromuro, hemicitrato, acetato, p-tosilato, L-tartrato, hemisuccinato y mesilato de amida de ácido 3-(4-bromo-2,6-difluorobenciloxi)-5-(3-(4-pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico que tiene la fórmula (I); la invención también se refiere a composiciones farmaceuticas que contienen las sales hidrocloruro, hemicitrato, acetato. P-tosilato, hemisuccinato y mesilato de formula (I). La invención se refiere además a métodos para tratar enfermedades hiperproliferativas, tales como cánceres en mamíferos, especialmente seres humanos, por administración de las sales anteriores, y a los métodos para preparar las formas cristalinas de las sales anteriores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25351300P | 2000-11-28 | 2000-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27039A1 true UY27039A1 (es) | 2002-07-31 |
Family
ID=22960587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27039A UY27039A1 (es) | 2000-11-28 | 2001-11-26 | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción |
Country Status (50)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| JP4511352B2 (ja) * | 2002-07-25 | 2010-07-28 | ファイザー・インク | 抗癌薬として有用なイソチアゾール誘導体 |
| GEP20074134B (en) * | 2002-08-19 | 2007-06-25 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases |
| CA2526636C (en) | 2003-05-20 | 2012-10-02 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
| CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
| NZ546447A (en) * | 2003-10-27 | 2009-02-28 | Merck & Co Inc | ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine succinate |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2005102327A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Dosage forms and methods of treatment using vegfr inhibitors |
| MXPA06012394A (es) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
| TW200538104A (en) * | 2004-05-17 | 2005-12-01 | Pfizer Prod Inc | Phenyl derivatives for the treatment of abnormal cell growth |
| JP2008510734A (ja) | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| BR122020011899B1 (pt) | 2006-06-16 | 2021-05-11 | H. Lundbeck A/S | processos para a preparação de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina e para a fabricação do sal de adição de ácido bromídrico correspondente |
| US7932390B2 (en) | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
| US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
| MX2010001636A (es) | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
| WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
| EP2596026B1 (en) | 2010-07-23 | 2020-04-08 | Trustees of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| WO2014152661A1 (en) | 2013-03-14 | 2014-09-25 | Panoptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
| RU2704810C2 (ru) * | 2014-09-17 | 2019-10-31 | Паноптика, Инк. | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза |
| WO2024140850A1 (zh) * | 2022-12-28 | 2024-07-04 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
-
2001
- 2001-11-19 EE EEP200300247A patent/EE200300247A/xx unknown
- 2001-11-19 DO DO2001000288A patent/DOP2001000288A/es unknown
- 2001-11-19 CA CA002430065A patent/CA2430065C/en not_active Expired - Lifetime
- 2001-11-19 KR KR1020057022534A patent/KR20050116401A/ko active IP Right Grant
- 2001-11-19 HU HU0302553A patent/HUP0302553A3/hu unknown
- 2001-11-19 BR BR0115621-7A patent/BR0115621A/pt not_active Application Discontinuation
- 2001-11-19 CZ CZ20031315A patent/CZ20031315A3/cs unknown
- 2001-11-19 EP EP01982663A patent/EP1337521B1/en not_active Expired - Lifetime
- 2001-11-19 JP JP2002546528A patent/JP2004514714A/ja not_active Withdrawn
- 2001-11-19 AP APAP/P/2001/002358A patent/AP2001002358A0/en unknown
- 2001-11-19 AT AT01982663T patent/ATE340786T1/de not_active IP Right Cessation
- 2001-11-19 NZ NZ525788A patent/NZ525788A/en unknown
- 2001-11-19 AU AU1420402A patent/AU1420402A/xx active Pending
- 2001-11-19 KR KR10-2003-7007057A patent/KR20030059275A/ko not_active Application Discontinuation
- 2001-11-19 SK SK586-2003A patent/SK5862003A3/sk unknown
- 2001-11-19 CN CNB018193285A patent/CN1231474C/zh not_active Expired - Fee Related
- 2001-11-19 SI SI200130630T patent/SI1337521T1/sl unknown
- 2001-11-19 EA EA200300424A patent/EA005859B1/ru not_active IP Right Cessation
- 2001-11-19 DE DE60123461T patent/DE60123461T2/de not_active Expired - Lifetime
- 2001-11-19 ES ES01982663T patent/ES2271086T3/es not_active Expired - Lifetime
- 2001-11-19 AU AU2002214204A patent/AU2002214204B2/en not_active Ceased
- 2001-11-19 IL IL15537101A patent/IL155371A0/xx unknown
- 2001-11-19 GE GE5216A patent/GEP20053652B/en unknown
- 2001-11-19 UA UA2003054858A patent/UA74221C2/uk unknown
- 2001-11-19 WO PCT/IB2001/002193 patent/WO2002044158A1/en active IP Right Grant
- 2001-11-19 DK DK01982663T patent/DK1337521T3/da active
- 2001-11-19 MX MXPA03004714A patent/MXPA03004714A/es active IP Right Grant
- 2001-11-19 PL PL01362079A patent/PL362079A1/xx not_active Application Discontinuation
- 2001-11-19 PT PT01982663T patent/PT1337521E/pt unknown
- 2001-11-19 YU YU36403A patent/YU36403A/sh unknown
- 2001-11-19 OA OA1200300137A patent/OA12532A/en unknown
- 2001-11-26 MY MYPI20015382A patent/MY136686A/en unknown
- 2001-11-26 AR ARP010105484A patent/AR031512A1/es not_active Application Discontinuation
- 2001-11-26 PE PE2001001179A patent/PE20020591A1/es not_active Application Discontinuation
- 2001-11-26 UY UY27039A patent/UY27039A1/es not_active Application Discontinuation
- 2001-11-27 US US09/993,640 patent/US6831091B2/en not_active Expired - Lifetime
- 2001-11-27 TW TW090129315A patent/TWI287542B/zh active
- 2001-11-27 SV SV2001000748A patent/SV2002000748A/es unknown
- 2001-11-27 HN HN2001000268A patent/HN2001000268A/es unknown
- 2001-11-27 PA PA20018533801A patent/PA8533801A1/es unknown
- 2001-11-27 GT GT200100237A patent/GT200100237A/es unknown
- 2001-11-27 TN TNTNSN01167A patent/TNSN01167A1/fr unknown
-
2003
- 2003-04-14 IS IS6788A patent/IS6788A/is unknown
- 2003-04-22 BG BG107752A patent/BG107752A/bg unknown
- 2003-04-24 CR CR6963A patent/CR6963A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303341A patent/ZA200303341B/en unknown
- 2003-05-13 MA MA27158A patent/MA26960A1/fr unknown
- 2003-05-20 HR HR20030408A patent/HRP20030408A2/hr not_active Application Discontinuation
- 2003-05-27 NO NO20032388A patent/NO325187B1/no unknown
- 2003-05-28 EC EC2003004628A patent/ECSP034628A/es unknown
-
2004
- 2004-03-22 HK HK04102071A patent/HK1059085A1/xx not_active IP Right Cessation
-
2006
- 2006-11-13 CY CY20061101645T patent/CY1106240T1/el unknown
-
2007
- 2007-10-29 JP JP2007279951A patent/JP4971946B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27039A1 (es) | Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción | |
| AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
| ECSP024393A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal | |
| AR032679A1 (es) | Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| UY27572A1 (es) | Formas de sal e-2-metoxi-n-(3-(4(3-metil-4-(6-metilpiridin-3-iloxi) fenilamino) quinazolin-6-il)alil) acetamida y procedimiento de producción | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR041635A1 (es) | Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen | |
| BRPI0507786A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos | |
| BRPI0410477A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto | |
| UY28374A1 (es) | Agentes terapéuticos | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| ATE512961T1 (de) | Amorphes nebivolol hydrochlorid und seine herstellung | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
| EA200300718A1 (ru) | Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств | |
| TW200714598A (en) | Urea derivatives, methods for their manufacture, and uses therefor | |
| UY27593A1 (es) | Nuevos compuestos | |
| AR044830A1 (es) | Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester | |
| BRPI0415203A (pt) | pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios | |
| EA200700807A1 (ru) | Новые циклические и ациклические пропеноны для лечения заболеваний цнс | |
| AR074593A1 (es) | Benzotiazol amidas para la deteccion del peptido beta amiloide | |
| BR0315839A (pt) | Derivados de prolina tendo afinidade para a subunidade alfa-2-delta do canal de cálcio | |
| BRPI0811245A2 (pt) | Composto de carbamoilóxi-aril-alcanoil-aril-piperazinas, composições farmacêuticas que compreendem o composto, e método para tratar dor, ansiedade e depressão administrando o composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20141107 |